Authors
Latest:
ARVO heads north to Vancouver for 2019 annual meeting‘From the Bench to Bedside and Back’ is focal point for this year’s conference
Latest:
Face-down positioning better after detached retina repairFace-down positioning is associated with a reduction in certain complications following macula-involving retinal displacement (RD) repair, according to researchers.
Latest:
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Latest:
A great leap forward in ophthalmic drug delivery?“[Gene therapy may] dramatically reduce frequency of treatments.”
Latest:
Tocilizumab effective for managing posterior segment inflammationImprovement in visual acuity, central retinal thickness, vitreous haze reported at 6 months
Latest:
MCO-010 optogenetic gene therapy for severe vision loss in Stargardt diseaseA mutation-agnostic optogenetic gene therapy is in development using multi-characteristic opsin (MCO) to sensitize the retinal bipolar cells to detect light.
Latest:
Survey: Retina specialists see need for alternative treatments for macular edema associated with noninfectious uveitisSurvey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.
Latest:
2023: What awaits ophthalmology in the year aheadAs we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Latest:
Anti-seizure drug gets boxed warning for eye damage risksThe FDA has approved changes to the drug label of the anti-seizure drug ezogabine (Potiga), underscoring risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration-all of which may become permanent.
Latest:
Migraines and retinal perfusion: A headache for physicians, patientsOptical coherence tomography angiography can detect microcirculatory disturbances during acute attacks.
Latest:
PALADIN subset finds improvement after 12 months with intravitreal implantAmong a subset of patients in the phase IV PALADIN study, there was improved visual acuity, improved macular thickness, and reduced treatment burden among patients treated with the intravitreal fluocinolone acetonide 0.2 µg (Iluvien implant) for DME.
Latest:
Intravitreal implant could bring significant cost savings to NHS EnglandA study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Latest:
Moorfields research provides hope for choroideremia curePreliminary research has shown that ataluren is effective in overriding the nonsense mutation in choroideremia patients, however, further research is needed.
Latest:
Case #2: Impressions and Clinical InsightsA retina specialist discusses impressions and key take away points from patient case.
Latest:
Emerging treatments for advanced dry AMDInvestigational pipeline provides promise for an unmet need.
Latest:
Review of the epidemiology of diabetic retinopathyThe prevalence of visual impairment and blindness caused by diabetic retinopathy is increasing worldwide. Early recognition, perhaps via a screening programme, and timely management would be of benefit.
Latest:
Review of the epidemiology of diabetic retinopathyThe prevalence of visual impairment and blindness caused by diabetic retinopathy is increasing worldwide. Early recognition, perhaps via a screening programme, and timely management would be of benefit.
Latest:
Parafoveal retinal vessel density assessment by OCTA in healthy eyesStudy aims to identify methodology for least amount of variation, greatest test-retest reliability
Latest:
Parafoveal retinal vessel density assessment by OCTA in healthy eyesStudy aims to identify methodology for least amount of variation, greatest test-retest reliability
Latest:
Parafoveal retinal vessel density assessment by OCTA in healthy eyesStudy aims to identify methodology for least amount of variation, greatest test-retest reliability
Latest:
Parafoveal retinal vessel density assessment by OCTA in healthy eyesStudy aims to identify methodology for least amount of variation, greatest test-retest reliability
Latest:
Parafoveal retinal vessel density assessment by OCTA in healthy eyesStudy aims to identify methodology for least amount of variation, greatest test-retest reliability
Latest:
Take-Home Points for the Treatment of AMD and DMEDavid A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
